Treating Type 2 Diabetes With Once-Weekly BYDUREON™ (exenatide extended-release for injectable suspension)

**Indications and Usage**
BYDUREON is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

- Because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans, prescribe only to patients for whom potential benefits are considered to outweigh potential risk.
- Not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.
- Not a substitute for insulin, should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and cannot be recommended for use with insulin.
- BYDUREON and BYETTA® (exenatide) injection both contain the same active ingredient, exenatide, and should not be used together.
- Exenatide has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, based on postmarketing data. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using BYDUREON; consider other antidiabetic therapies for these patients.

**BOXED WARNING: RISK OF THYROID C-CELL TUMORS**
Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies. BYDUREON is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with BYDUREON. Patients should be counseled regarding the risk and symptoms of thyroid tumors. Please see additional Important Safety Information on pages 6 and 7 and the accompanying Prescribing Information and Medication Guide.
Background
The discovery of a group of gut hormones called incretins has spurred the development of a class of incretin-based medications for the treatment of type 2 diabetes mellitus (T2DM). The pathogenesis of T2DM is complex and classically associated with progressive beta-cell failure (relative insulin deficiency) and insulin resistance in fat and muscle cells.1 Glucose homeostasis is known, however, to be maintained by complex interactions involving insulin, glucagon, and the incretin hormones. The latter are released by enteroendocrine cells in the gut in response to meal ingestion. Incretin dysfunction, along with a number of other important physiological defects, have been implicated in the pathogenesis of T2DM. Incretin-based therapies, aimed at restoring incretin activity in people with T2DM, have been shown to be effective therapies in this population.

Despite an increasing recognition of the importance of reaching glycemic goals and a greater emphasis on diabetes care, only 55% of adults with T2DM achieved a glycosylated hemoglobin (A1C) below 7.0%, according to the National Health and Nutrition Examination Survey (NHANES).2 Furthermore, even in patients that are compliant with their medications, the benefits of lifestyle interventions and oral hypoglycemic therapy may not be durable, which is likely due to the progressive nature of the disease.3 As noted above, traditional models of T2DM disease progression have emphasized the core defects of peripheral insulin resistance, increased hepatic gluconeogenesis, and progressive loss of pancreatic beta-cell function (resulting in insulin deficiency).4 These changes make the pathophysiology of T2DM quite complex.4

Incretin-Based Medications
First identified in the 1960s, the “incretin effect” showed that insulin secretion is greater in response to the oral intake of a meal when compared to intravenous glucose administration.5,6 Subsequently, the incretin effect was shown to be due primarily to the secretion of two incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).7 Combined, these 2 hormones account for ~70% of insulin secretion following glucose ingestion.8 The effects of GLP-1 are mediated by binding of the hormone to GLP-1 receptors.9 GLP-1 has been shown to stimulate glucose-dependent insulin secretion, suppress glucagon secretion, slow gastric emptying, and decrease caloric intake.10 Insulin release in response to GLP-1 is glucose-dependent, meaning that insulin release is stimulated only when blood glucose levels are elevated, and insulin secretion decreases as blood glucose levels approach normal. Circulating GLP-1 is short-lived, with a half-life of less than 2 minutes due to its rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).11

The incretin response is disrupted in people with T2DM. Studies have shown, however, that the administration of exogenous GLP-1 is capable of correcting this defect.12 In early clinical studies involving patients with T2DM, continuous exposure to GLP-1 demonstrated improved glycemic control mimicking that of healthy subjects.13,14 The clinical utility of natural GLP-1 is
limited, however, by its rapid degradation by the DPP-4 enzyme. Two treatment approaches have thus far been developed to overcome these limitations: GLP-1 receptor agonists, which provide a pharmacologic dose of GLP-1 analog designed to resist DPP-4 degradation, and DPP-4 inhibitors, which slow the inactivation of endogenous incretin hormones by inhibiting the DPP-4 enzyme. Clinically, DPP-4 inhibitors are oral therapies that can improve post-prandial insulin secretion and are generally weight neutral.\textsuperscript{15} The injectable GLP-1 receptor agonists have demonstrated efficacy in terms of stimulating glucose-dependent insulin secretion and are also capable of inducing weight loss in people with T2DM.\textsuperscript{16} BYDUREON (exenatide extended-release for injectable suspension) is a GLP-1 receptor agonist that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM in multiple clinical settings. BYDUREON carries a boxed warning for potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma. Because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans, BYDUREON is not recommended as first-line therapy for patients uncontrolled on diet and exercise alone.\textsuperscript{15}

BYDUREON: A New Approach To T2DM Treatment

Microsphere technology. BYDUREON is the first once-weekly GLP-1 receptor agonist approved in the United States for the treatment of T2DM. BYDUREON utilizes patented biodegradable microspheres to deliver a controlled release of exenatide (\textsuperscript{16}FIGURE 1). The microspheres are composed of polylactide-co-glycolide acid polymer, which has been used in other therapeutic applications to encapsulate small molecules, peptides, and proteins.\textsuperscript{17} Immediately following subcutaneous injection, the BYDUREON microspheres aggregate, and exenatide at or near the surface of the microspheres diffuses. Over time, as the microspheres degrade, exenatide is continuously released into the circulation. The microsphere polymer is completely metabolized and eliminated as carbon dioxide and water.\textsuperscript{17} This process results in a controlled release of exenatide for a continuous presence of GLP-1 receptor activation. Once steady state is achieved, therapeutic levels of exenatide are maintained with once-weekly dosing.

Pharmacokinetic profile of BYDUREON. Following initiation of once-weekly BYDUREON, plasma levels gradually increase over 6 to 7 weeks. Steady-state levels of exenatide are maintained thereafter with once-weekly dosing. After 2 weeks of therapy, decreases in fasting plasma glucose (FPG) are observed in patients with T2DM, and by week 14 (the earliest time point at which it was examined), post-prandial glucose (PPG) levels also improve.\textsuperscript{18,19}

Clinical efficacy. Efficacy data from a 24-week, randomized, open-label clinical trial compared the addition of BYDUREON 2 mg QW (n = 129) to BYETTA\textsuperscript{®} (exenatide) injection 10 mcg BID (n = 123) in adults with T2DM inadequately controlled on lifestyle intervention and/or oral antidiabetic therapy (metformin, SFU, thiazolidinedione, or a combination of any 2 of these agents).\textsuperscript{20} Study participants in the BYDUREON and BYETTA arms had an average baseline (BL) A1C of 8.5% and 8.4%, respectively, and weighed an average of 213.8 lb and 207.9 lb, respectively. The average duration of T2DM was 7 years for both treatment groups. Participants treated with BYDUREON experienced a mean A1C reduction of 1.6% compared to a mean reduction of 0.9% for those receiving BYETTA (P < .001). Additionally, the proportion of patients reaching an A1C of <7% was 58% in the BYDUREON arm vs 30% in the BYETTA arm (P < .001). BYDUREON treatment was also associated with a reduction in mean FPG of -25 mg/dL at 24 weeks compared to a mean reduction of -5 mg/dL in the BYETTA group. And although BYDUREON is not indicated for weight loss,
BYDUREON patients lost an average of 5.1 lb, which was similar to BYETTA® (exenatide) injection (3.1 lb). BYDUREON has also been studied in 2 separate 26-week clinical trials vs Januvia (sitagliptin), a DPP-4 inhibitor that is administered as a once-daily oral agent. In the first trial, T2DM patients with inadequate glycemic control on metformin alone were randomized to receive BYDUREON 2 mg QW (n = 160) or the maximum approved dose of Januvia (100 mg QD; n = 160).21 Patients in the BYDUREON arm experienced a mean A1C reduction of 1.5% from a BL of 8.6% vs 0.9% for Januvia patients (BL = 8.5%; P < .0001). Patients in the BYDUREON arm lost a mean 5.1 lb while the Januvia group lost a mean 1.8 lb (P = .0002). As a secondary endpoint, 62% of BYDUREON patients achieved an A1C goal of ≤7% vs 35% for Januvia. In the second trial, patients with T2DM who were drug-naïve were randomized to receive BYDUREON or Januvia.22 A mean A1C reduction of 1.5% was achieved in the BYDUREON arm, with participants in the Januvia arm achieving a mean A1C reduction of 1.2% (P < .001).22 Additionally, as secondary endpoints, patients in the BYDUREON arm lost 4.4 lb while those receiving Januvia lost 1.8 lb (P < .001), and 64% of patients achieved an A1C goal of ≤7% vs 46% for Januvia.

Collectively, clinical trial data with BYDUREON demonstrated improvements in glycemic control, and although not indicated for weight loss, participants receiving BYDUREON treatment realized a decrease in their weight on average.

Safety
Boxed Warning. Exenatide extended-release causes thyroid C-cell tumors at clinically relevant exposures in rats. Because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans, BYDUREON is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.

Contraindications. BYDUREON is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Additionally, BYDUREON is contraindicated for use in patients with known hypersensitivity to exenatide or any components of the formulation.

Warnings.
• Cases of pancreatitis in people using exenatide have been reported, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis. BYDUREON should be discontinued promptly if pancreatitis is suspected and should not be restarted if a diagnosis of pancreatitis is made. Likewise, other antidiabetic therapies should be considered in individuals with a history of pancreatitis.
• There is an increased risk of hypoglycemia when BYDUREON is used in combination with a sulfonylurea. If initiating BYDUREON in an individual on sulfonylurea therapy, consider reducing the sulfonylurea dose.
• Postmarketing reports of renal impairment have been reported with exenatide. BYDUREON is not recommended in patients with severe renal impairment or end-stage renal disease and should be used with caution in those with renal transplantation or moderate renal impairment.
• BYDUREON is not recommended in individuals with severe gastrointestinal disease, such as gastroparesis.
• Postmarketing reports of serious hypersensitivity reactions with exenatide have been reported. In such cases, BYDUREON should be discontinued in addition to any other suspected medications and medical advice should be sought promptly.
• Clinical studies establishing conclusive evidence of macrovascular risk reduction have not been performed with BYDUREON or any other antidiabetic drug.

Adverse Reactions
Some of the most frequently reported adverse events associated with BYDUREON in clinical trials were nausea, diarrhea, headache, and vomiting. Nausea was generally mild and tended to decrease over time. While nausea was the most common side effect with BYDUREON therapy, the incidence was less than was seen with twice-daily BYETTA. In the 24-week clinical trial of BYDUREON vs BYETTA, the rates of nausea were 14% and 35%, respectively.16 In a separate 30-week clinical trial vs BYETTA, rates of nausea were 27% vs 34%.16 Injection-site reactions (itching, redness) are more common in BYDUREON-treated patients vs patients receiving comparator injections. In addition, small, asymptomatic, subcutaneous injection-site
nODULES ARE SEEN WITH THE USE OF BYDUREON. THESE ARE CONSISTENT WITH THE KNOWN PROPERTIES OF THE MICROSPHERES USED IN BYDUREON AND TYPICALLY RESOLVE WITHIN 3 TO 6 WEEKS. IN CLINICAL TRIALS, THERE WERE NO REPORTS OF MAJOR HYPOGLYCEMIA, ALTHOUGH THE RISK OF MINOR HYPOGLYCEMIA WAS INCREASED WITH CONCOMITANT SFU USE.

**Administration & Dosing**

BYDUREON is administered once every 7 days (weekly) at any time of day, independent of meals. BYDUREON is administered as a subcutaneous injection in the abdomen, thigh, or upper arm regions. Patients should be counseled to use a different injection site each week when injecting in the same regions. The steps for administration are straightforward (connect, shake, and inject; see **FIGURE 2**), and BYDUREON is intended for patient self-administration. BYDUREON is provided in cartons containing 4 single-dose trays; the trays should be stored under refrigeration.

**BYDUREON in T2DM Treatment**

A cornerstone of the ADA guidelines for pharmacologic treatment of T2DM is the timely augmentation of therapy with additional agents in order to achieve and maintain individualized A1C goals. The 2012 Position Statement from the ADA and the European Association for the Study of Diabetes (EASD) advocates for a “patient-centered” approach to treatment and emphasizes not only glucose-lowering efficacy, but also potential side effects, weight loss, and low risk of hypoglycemia. Treatment with metformin is recommended for most patients at or soon after diagnosis, followed by dual-therapy if glycemic goals are not being met after ~3 months. When progressing to dual-therapy, the ADA/EASD recommends adding 1 of 5 second-line agents: SFU, TZD, a GLP-1 receptor agonist like BYDUREON, DPP-4 inhibitor, or basal insulin. Choice is based on patient and drug characteristics, with the overriding goal of improving glycemic control while minimizing side effects. GLP-1 receptor agonists are recommended as an option for add-on therapy to metformin due to their efficacy in terms of A1C reduction, potential for weight loss, and low risk of hypoglycemia. The American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) recommends a GLP-1 receptor agonist, like BYDUREON, as a preferred agent for combination therapy (ie, add-on to metformin, or metformin plus an SFU or a thiazolidinedione) in patients not meeting glycemic goals with monotherapy due to its low risk of hypoglycemia when not used with an SFU and the potential to provide weight loss. The continuous glycemetic control provided with BYDUREON, along with the potential for weight loss and low risk of hypoglycemia, are meaningful considerations for achieving treatment goals in patients with T2DM. 

Please see Important Safety Information on pages 6 and 7, and the accompanying Prescribing Information and Medication Guide.
BOXED WARNING: RISK OF THYROID C-CELL TUMORS

Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON (exenatide extended-release for injectable suspension) causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies. BYDUREON is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with BYDUREON. Patients should be counseled regarding the risk and symptoms of thyroid tumors.

Contraindications

- BYDUREON is contraindicated in patients with known prior severe hypersensitivity reactions to exenatide or to any of the product components.

Warnings and Precautions

- Based on postmarketing data, exenatide has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. After initiation of BYDUREON, observe patients carefully for pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting). If pancreatitis is suspected, BYDUREON should be discontinued promptly and should not be restarted if pancreatitis is confirmed.

- Increased risk of hypoglycemia when used in combination with glucose-independent insulin secretagogues (eg, sulfonylureas). Clinicians may consider reducing the sulfonylurea (SFU) dose.

- Should not be used in patients with severe renal impairment or end-stage renal disease. Use with caution in patients with renal transplantation or moderate renal failure. Postmarketing reports of altered renal function with exenatide, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation.

- Not recommended in patients with severe gastrointestinal disease (eg, gastroparesis).

- Patients may develop antibodies to exenatide. In 5 registration trials, attenuated glycemic response was associated in 6% of BYDUREON-treated patients with antibody formation. If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy.

- Postmarketing reports of serious hypersensitivity reactions (eg, anaphylaxis and angioedema). If this occurs, patients should discontinue BYDUREON and other suspect medications and promptly seek medical advice.

- No clinical studies establishing conclusive evidence of macrovascular risk reduction with BYDUREON or any other antidiabetic drug.

Withdrawals

- In 5 comparator-controlled, 24- to 30-week BYDUREON trials, the incidence of withdrawal due to adverse events was 4.9% for BYDUREON, 4.9% for BYETTA® (exenatide) injection, and 2.0% for other comparators. The most common adverse reactions leading to withdrawal for BYDUREON, BYETTA, and comparators respectively were: nausea (0.5%, 1.5%, 0.3%); injection-site nodule (0.5%, 0.0%, 0.0%); diarrhea (0.3%, 0.4%, 0.3%); injection-site reaction (0.2%, 0.0%, 0.0%); and headache (0.2%, 0.0%, 0.0%). One percent of BYDUREON patients withdrew due to injection-site adverse reactions.

Adverse Reactions (≥5%)

- BYDUREON vs BYETTA: 24-week trial, nausea (14% vs 35%), diarrhea (9.3% vs 4.1%), injection-site erythema (5.4% vs 2.4%); 30-week trial, nausea (27% vs 33.8%), diarrhea (16.2% vs 12.4%), vomiting (10.8% vs 18.6%), injection-site pruritus (18.2% vs 1.4%), constipation (10.1% vs 6.2%), gastroenteritis viral (8.8% vs 5.5%), gastroesophageal reflux disease (7.4% vs 4.1%), dyspepsia (7.4% vs 2.1%), injection-site erythema (7.4% vs 0.0%), fatigue (6.1% vs 3.4%), headache (6.1% vs 4.8%), injection-site hematoma (5.4% vs 11.0%).

- BYDUREON vs titrated insulin glargine: nausea (12.9% vs 1.3%), headache (9.9% vs 7.6%), diarrhea (9.4% vs 4.0%), injection-site nodule (6.0% vs 0.0%).
• Combination trial vs sitagliptin and pioglitazone: nausea (24.4% vs 9.6% and 4.8%), diarrhea (20.0% vs 9.6% and 7.3%), vomiting (11.3% vs 2.4% and 3.0%), headache (9.4% vs 9.0% and 5.5%), constipation (6.3% vs 3.6% and 1.2%), fatigue (5.6% vs 0.6% and 3.0%), dyspepsia (5.0% vs 3.6% and 2.4%), decreased appetite (5.0% vs 1.2% and 0.0%), injection-site pruritus (5.0% vs 4.8% and 1.2%).

• Monotherapy trial vs sitagliptin, pioglitazone, and metformin: nausea (11.3% vs 3.7%, 4.3%, and 6.9%), diarrhea (10.9% vs 5.5%, 3.7%, and 12.6%), injection-site nodule (10.5% vs 6.7%, 3.7%, and 10.2%), constipation (8.5% vs 2.5%, 1.8%, and 3.3%), headache (8.1% vs 9.2%, 8.0%, and 12.2%), dyspepsia (7.3% vs 1.8%, 4.9%, and 3.3%).

• Injection-site reactions were observed more frequently in BYDUREON-treated patients (17.1%) vs patients treated with BYETTA (12.7%), titrated insulin glargine (1.8%), or placebo injection (6.4%-13.0%). Injection-site reactions were observed in 14.2% of antibody-positive patients vs 3.1% of antibody-negative patients, with higher incidence in those with higher-titer antibodies. BYETTA-treated patients had similar incidence between antibody-positive and antibody-negative patients (5.8% vs 7.0%). Small, asymptomatic, subcutaneous injection-site nodules are seen with the use of BYDUREON.

Hypoglycemia
• No major hypoglycemia was reported for BYDUREON- or comparator-treated patients in five 24- to 30-week trials. Minor hypoglycemia incidences for BYDUREON vs comparator-treated patients were as follows: 24-week trial vs BYETTA: with SFU, 12.5% vs 11.8%; without SFU, 0.0% for both; 30-week trial vs BYETTA: with SFU, 14.5% vs 15.4%; without SFU, 0.0% vs 1.1%; monotherapy trial vs sitagliptin, pioglitazone, and metformin: 2.0% vs 0.0% (all comparators); combination trial vs sitagliptin and pioglitazone: 1.3% vs 3.0% and 1.2%; vs titrated insulin glargine, with SFU, 20.0% vs 43.9%; without SFU, 3.7% vs 19.1%.

Drug Interactions
• BYDUREON slows gastric emptying and can reduce the rate of absorption of orally administered drugs. Use with caution with oral medications.
• Postmarketing reports of increased international normalized ratio (INR) sometimes associated with bleeding with concomitant use of warfarin. Monitor INR frequently until stable upon initiation or alteration of BYDUREON.

Use in Specific Populations
• Based on animal data, BYDUREON may cause fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
• Caution should be exercised when administered to a nursing woman.
• Use in pediatric patients is not recommended as safety and effectiveness have not been established.

For complete safety profile and other important prescribing considerations, see the accompanying Prescribing Information and Medication Guide.
COUNSELING CORNER

The following series of questions and answers serves as a patient education aid to assist healthcare professionals in counseling patients with type 2 diabetes who have been prescribed BYDUREON (exenatide extended-release for injectable suspension).

Q. How does BYDUREON work all week?  
- Medicine is contained in microspheres  
- Microspheres release medicine continuously over time  
- Medicine works only when blood sugar levels are high

Q. When do I take BYDUREON?  
- Once every 7 days on the same day each week  
- Any time of the day, with or without food

Q. If I have to change my Dosing Day, how do I do that?  
- New Dosing Day must be at least 3 days after your last dose  
- Do not take 2 doses of BYDUREON less than 3 days apart

Q. What are the most common side effects?  
- Nausea is most common; usually occurs at the start of treatment and should decrease over time for most patients  
- Diarrhea, vomiting, and constipation  
- Itching or redness at injection site  
- Small, raised bump within 2 to 4 weeks of injecting BYDUREON, which may not be visible to the naked eye and should go away on its own within 3 to 6 weeks

Q. What are some of the serious side effects?  
- Potential increased risk of thyroid tumors  
- Inflammation of the pancreas (pancreatitis)  
- Low blood sugar (hypoglycemia)  
- Kidney problems (renal impairment)  
- Stomach problems (gastrointestinal disease)  
- Allergic reaction (hypersensitivity)

Q. What changes might I notice?  
- Better blood sugar levels before eating (after 2 weeks)  
- Patients switching from BYETTA (exenatide) injection: blood sugar levels may be higher than usual as the medicine is gradually released; this is expected and should improve within about 2 weeks  
- Reduced A1C within a few months

Please see Important Safety Information on pages 6 and 7, and the accompanying Prescribing Information and Medication Guide.
Introducing BYDUREON: ORDER NOW!

The first and only once-weekly treatment for type 2 diabetes is now available to order

- In multiple clinical trials, BYDUREON delivered powerful A1C reductions and helped patients achieve recommended A1C goals

The trade pack (carton) should not be opened nor should a single-dose tray be sold individually.

- BYDUREON will be dispensed in a trade pack (carton) containing 4 single-dose trays. Remind patients to read the enclosed Medication Guide contained in the trade pack. For more information, please visit www.BYDUREONHCP.com.

Special storage requirements

- BYDUREON should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) and protected from light until preparing for use. Do not freeze the BYDUREON trade pack (carton). After BYDUREON is dispensed, advise patients to keep it in the refrigerator, but if needed, when traveling for example, patients can keep a single-dose tray out of the refrigerator for a total of 4 weeks at a temperature no higher than 77°F (25°C).

Information

- For order information contact your wholesaler. For product or storage and handling questions, or product returns, call Amylin Customer Service at 1-866-208-1657.

Indication and Usage

BYDUREON is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

- Because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans, prescribe only to patients for whom potential benefits are considered to outweigh potential risk.
- Not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.
- Not a substitute for insulin, should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and cannot be recommended for use with insulin.
- BYDUREON and BYETTA® (exenatide) injection both contain the same active ingredient, exenatide, and should not be used together.
- Exenatide has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, based on postmarketing data. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using BYDUREON; consider other antidiabetic therapies for these patients.

BOXED WARNING:
RISK OF THYROID C-CELL TUMORS

Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies. BYDUREON is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with BYDUREON. Patients should be counseled regarding the risk and symptoms of thyroid tumors.

To learn more, visit www.BYDUREONHCP.com/pharmacist

For additional Important Safety Information, see pages 6 to 7 and the accompanying Prescribing Information and Medication Guide.
INDICATIONS AND USAGE
BYDUREON is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings (1.1, 1.4).

BYDUREON is an extended-release formulation of exenatide. Do not co-administer with BYETTA.

Important Limitations of Use
• Not recommended as first-line therapy for patients inadequately controlled on diet and exercise (5.1).
• Should not be used to treat type 1 diabetes or diabetic ketoacidosis (1.2).
• Not recommended as first-line therapy for patients inadequately controlled on diet and exercise with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (5.1).

DOSE AND ADMINISTRATION
BYDUREON is 2 mg exenatide for extended-release injectable suspension.

DOSAGE FORMS AND STRENGTHS
BYDUREON is 2 mg exenatide for extended-release injectable suspension.

CONTRAINDICATIONS
• Do not use if personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4.4).
• Do not use if history of serious hypersensitivity to exenatide or any product components (4.2).

WARNINGS AND PRECAUTIONS
• Thyroid C-cell tumors in animals: Human relevance unknown. Counsel patients regarding the risk of medullary thyroid carcinoma and the symptoms of thyroid tumors (5.1).
• Pancreatitis: Postmarketing reports with exenatide, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
• Hypoglycemia: Increased risk when BYDUREON is used in combination with a sulfonylurea. Consider reducing the sulfonylurea dose (5.3).
• Renal Impairment: Postmarketing reports with exenatide, sometimes requiring hemodialysis and kidney transplantation. Not recommended if severe renal impairment or end-stage renal disease. Use with caution in patients with renal transplantation or moderate renal impairment (5.4, 8.6, 12.3).
• Severe Gastrointestinal Disease: Not recommended if severe gastrointestinal disease (e.g., gastroparesis) (5.5).
• Hypersensitivity: Postmarketing reports with exenatide of serious hypersensitivity reactions (e.g. anaphylaxis and angioedema). In such cases, patients are to discontinue BYDUREON and other suspect medications and promptly seek medical advice (5.7).
• Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with BYDUREON or any other antidiabetic drug (5.8).

ADVERSE REACTIONS
• Most common (≥5%) and occurring more frequently than comparator in clinical trials: nausea, diarrhea, headache, vomiting, constipation, injection site pruritus, injection site nodule, and dyspepsia (5.3, 6.1).

• Monitor INR frequently until stable upon initiation of BYDUREON therapy (7.2, 6.2).

17 PATIENT COUNSELING INFORMATION
See full prescribing information for complete boxed warning.

WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.

• Exenatide extended-release causes thyroid C-cell tumors at clinically relevant exposures in rats. It is unknown whether BYDUREON causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies (5.1).
• BYDUREON is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (5.1).

FULL PRESCRIBING INFORMATION: CONTENTS*
• Sections or subsections omitted from the full prescribing information are not listed.

1 INDICATIONS AND USAGE
1.1 Type 2 Diabetes Mellitus
1.2 Important Limitations of Use

2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosing
2.2 Administration
2.3 Changing from BYETTA to BYDUREON

3 DOSAGE FORMS AND STRENGTHS
3.1 Medullary Thyroid Carcinoma
3.2 Hypersensitivity

4 CONTRAINDICATIONS
4.1 Medullary Thyroid Carcinoma
4.2 Hypersensitivity

5 WARNINGS AND PRECAUTIONS
5.1 Risk of Thyroid C-cell Tumors
5.2 Acute Pancreatitis
5.3 Hypoglycemia
5.4 Renal Impairment
5.5 Gastrointestinal Disease
5.6 Immune Reaction
5.7 Hypersensitivity
5.8 Macrococclusive Outcomes

6 ADVERSE REACTIONS
6.1 Clinical Trial Experience
6.2 Post-Marketing Experience

7 DRUG INTERACTIONS
7.1 Orally Administered Drugs
7.2 Warfarin

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Nursing Mothers
8.3 Pediatric Use
8.4 Geriatric Use
8.5 Renal Impairment
8.6 Hypertensive Use

10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
13.1 Carcinoegensis, Mutagenesis, Impairment of Fertility
13.2 Reproductive and Developmental Toxicology

14 CLINICAL STUDIES
14.1 24-Week Comparator-Controlled Study

16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION
17.1 Risk of Thyroid C-cell Tumors
17.2 Risk of Pancreatitis
17.3 Risk of Hypoglycemia
17.4 Risk of Renal Impairment
17.5 Risk of Hypersensitivity Reactions
17.6 Use in Pregnancy
17.7 Instructions

Revised: 01/2012
5.1 Risk of Thyroid C-cell Tumors
BYDUREON is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or in patients with thyroid nodules noted on physical examination or neck imaging. If a hypersensitivity reaction occurs, the patient should discontinue BYDUREON. Anti-exenatide antibodies may be developed in patients treated with BYDUREON. In 6% of BYDUREON-treated patients, antibody formation was associated with an attenuated glycemic response. If a hypersensitivity reaction occurs, the patient should discontinue BYDUREON. Patients may develop antibodies to exenatide following treatment with BYDUREON. Anti-exenatide antibodies were measured in all BYDUREON-treated patients in the five comparator-controlled 24-30 week studies of BYDUREON. In 6% of BYDUREON-treated patients, antibody formation was associated with an attenuated glycaemic response. If a hypersensitivity reaction occurs, the patient should discontinue BYDUREON and other suspect medications and promptly seek medical advice [see Adverse Reactions (6.7)].

5.2 Acute Pancreatitis
BYDUREON is contraindicated in patients with severe renal impairment (creatinine clearance < 10 mL/min) or end-stage renal disease and should be used with caution in patients with renal transplantation [see Use in Specific Populations (8.6) Clinical Pharmacology (12.2)]. BYDUREON has not been studied in patients with end-stage renal disease or severe renal impairment. There have been postmarketing reports of altered renal function with exenatide, including increased serum creatinine, renal impairment, worsening chronic renal failure and acute renal failure, sometimes requiring hemodialysis or kidney transplantation. Some of these events occurred in patients receiving one or more pharmacologic agents known to affect renal function or hydration status such as angiotensin converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, or diuretics. Some events occurred in patients who had been experiencing nausea, vomiting, or diarrhea, with or without dehydration. Reversibility of altered renal function has been observed in many cases with supportive treatment and discontinuation of potentially causative agents, including exenatide. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies.

5.3 Hypoglycemia
BYDUREON is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)]. BYDUREON must be injected immediately after the powder is suspended in the diluent and transferred to the syringe. BYDUREON is administered as a single dose of 2 mg once every seven days (weekly). The dose can be administered at any time of the day, with or without meals.

2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosing
BYDUREON (2 mg per dose) should be administered once every seven days (weekly). The dose can be administered at any time of the day, with or without meals.

2.2 Administration
BYDUREON is intended for patient self-administration. BYDUREON is provided in a single-dose tray containing one vial of 2 mg exenatide, one vial connector, one perflutrol sodium chloride and two needles (one for use only as a spacer) [see How Supplied/Storage and Handling (16.7)]. Do not substitute needles or any other components in the tray. BYDUREON must be injected immediately after the powder is suspended in the diluent on transfer to the syringe. BYDUREON is administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm area. Advise patients to use a different injection site each week when injecting in the same region. BYDUREON must not be administered intravenously or intramuscularly.

See the BYDUREON Instructions for Use for complete administration instructions with illustrations. The instructions can also be found at www.bydureon.com.

2.3 Changing from BYETTA to BYDUREON
BYDUREON is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

4.1 Medullary Thyroid Carcinoma
BYDUREON is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies. Exenatide extended-release caused a statistically significant increase in malignant thyroid C-cell carcinomas in male and female mice and rats at clinically relevant exposures. Exenatide extended-release caused a statistically significant increase in malignant thyroid C-cell carcinomas in male and female mice and rats at clinically relevant exposures. It is unknown whether BYDUREON will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors could not be determined by clinical or nonclinical studies. Serum calcitonin was not assessed in the clinical trials supporting the approval of BYDUREON [see Clinical Pharmacology (12.1)]. Serum calcitonin is a biomarker of MTC. Patients with MTC usually have calcitonin values >50 ng/mL.

5.8 Macrovascular Outcomes
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with BYDUREON or any other antidiabetic drug.

6 ADVERSE REACTIONS
6.1 Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of BYDUREON was assessed in five comparator-controlled trials, in patients who entered the studies not achieving adequate glycaemic control on their current therapy. In a double-blind 26 week trial, patients on diet and exercise were treated with BYDUREON 2 mg once every seven days (weekly), sitagliptin 100 mg daily, pioglitazone 45 mg daily, or metformin 2000 mg daily. In a double-blind 26 week trial, patients on metformin were treated with BYDUREON 2 mg once every seven days (weekly), sitagliptin 100 mg daily, or pioglitazone 45 mg daily. In an open-label 26 week trial, patients on metformin or metformin plus sulfonylurea were treated with BYDUREON 2 mg once every seven days (weekly) or optimized insulin glargine. In two open-label trials patients on diet or exercise, or metformin, a sulfonylurea, a thiazolidinedione or combination of oral agents were treated with BYDUREON 2 mg once every seven days (weekly) or BYETTA 10 mg twice daily.

Withdrawals
The incidence of withdrawal due to adverse events was 4.9% (N=45) for BYDUREON-treated patients, 4.9% (N=42) for BYETTA-treated patients and 2.0% (N=33) for other comparator-treated patients in the five comparator-controlled 24-30 week trials. The most common adverse reactions leading to withdrawal for BYDUREON-treated patients were nausea 0.5% (N=1) versus 1.5% (N=4) for BYETTA and 0.3% (N=3) for other comparators, injection site nodule 0.5% (N=1) versus 0.5% (N=1) for BYETTA and 0.0% (N=0) for other comparators, injection site pain 0.0% (N=0) versus 0.0% (N=0) for BYETTA and 0.6% (N=1) for other comparators and headache 0.2% (N=1) versus 0.0% (N=0) for BYETTA and 0.0% for other comparators.

BYDUREON is contraindicated in patients with severe renal impairment (creatinine clearance < 10 mL/min) or end-stage renal disease and should be used with caution in patients with renal transplantation [see Use in Specific Populations (8.6) Clinical Pharmacology (12.2)]. BYDUREON has not been studied in patients with end-stage renal disease or severe renal impairment.

BYDUREON is contraindicated in patients with severe renal impairment (creatinine clearance < 10 mL/min) or end-stage renal disease and should be used with caution in patients with renal transplantation [see Use in Specific Populations (8.6) Clinical Pharmacology (12.2)]. BYDUREON has not been studied in patients with end-stage renal disease or severe renal impairment.

BYDUREON is contraindicated in patients with severe renal impairment (creatinine clearance < 10 mL/min) or end-stage renal disease and should be used with caution in patients with renal transplantation [see Use in Specific Populations (8.6) Clinical Pharmacology (12.2)]. BYDUREON has not been studied in patients with end-stage renal disease or severe renal impairment.

BYDUREON is contraindicated in patients with severe renal impairment (creatinine clearance < 10 mL/min) or end-stage renal disease and should be used with caution in patients with renal transplantation [see Use in Specific Populations (8.6) Clinical Pharmacology (12.2)]. BYDUREON has not been studied in patients with end-stage renal disease or severe renal impairment.
Table 1: Incidence (% of subjects) and Rate (episodes/subject year) of Minor† hypoglycemia in the Monotherapy and in the Combination Therapy Trials

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>BYDUREON 2 mg (% of intent-to-treat patients)</th>
<th>Sitagliptin 100 mg (% of intent-to-treat patients)</th>
<th>Pioglitazone 45 mg (% of intent-to-treat patients)</th>
<th>Metformin 2000 mg (% of intent-to-treat patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>26-Week Monotherapy</td>
<td>2.0% (0.05)</td>
<td>0.0% (0.00)</td>
<td>0.0% (0.00)</td>
<td>N/A</td>
</tr>
<tr>
<td>26-Week Add-on to Metformin</td>
<td>1.3% (0.03)</td>
<td>3.0% (0.12)</td>
<td>1.2% (0.03)</td>
<td>N/A</td>
</tr>
<tr>
<td>26-Week Add-on to Metformin or Sitagliptin</td>
<td>20.0% (1.11)</td>
<td>41.9% (2.87)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Note: Percentages are based on the number of intent-to-treat patients.
N = The number of intent-to-treat patients.

Table 2: Treatment-Emergent Adverse Reactions Reported in ≥5% of BYDUREON-Treated Patients in Monotherapy and in the Combination Therapy Trials

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>BYDUREON 2 mg (% of intent-to-treat patients)</th>
<th>Sitagliptin 100 mg (% of intent-to-treat patients)</th>
<th>Pioglitazone 45 mg (% of intent-to-treat patients)</th>
<th>Metformin 2000 mg (% of intent-to-treat patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>26-Week Monotherapy</td>
<td>2.0% (0.05)</td>
<td>0.0% (0.00)</td>
<td>0.0% (0.00)</td>
<td>N/A</td>
</tr>
<tr>
<td>26-Week Add-on to Metformin</td>
<td>1.3% (0.03)</td>
<td>3.0% (0.12)</td>
<td>1.2% (0.03)</td>
<td>N/A</td>
</tr>
<tr>
<td>26-Week Add-on to Metformin or Sitagliptin</td>
<td>20.0% (1.11)</td>
<td>41.9% (2.87)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Note: Percentages are based on the number of intent-to-treat patients.
N = The number of intent-to-treat patients.

Table 3: Treatment-Emergent Adverse Reactions Reported in ≥5% of BYDUREON-Treated Patients in Monotherapy and in the Combination Therapy Trials

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>BYDUREON 2 mg (% of intent-to-treat patients)</th>
<th>Sitagliptin 100 mg (% of intent-to-treat patients)</th>
<th>Pioglitazone 45 mg (% of intent-to-treat patients)</th>
<th>Metformin 2000 mg (% of intent-to-treat patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>26-Week Monotherapy</td>
<td>2.0% (0.05)</td>
<td>0.0% (0.00)</td>
<td>0.0% (0.00)</td>
<td>N/A</td>
</tr>
<tr>
<td>26-Week Add-on to Metformin</td>
<td>1.3% (0.03)</td>
<td>3.0% (0.12)</td>
<td>1.2% (0.03)</td>
<td>N/A</td>
</tr>
<tr>
<td>26-Week Add-on to Metformin or Sitagliptin</td>
<td>20.0% (1.11)</td>
<td>41.9% (2.87)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Note: Percentages are based on the number of intent-to-treat patients.
N = The number of intent-to-treat patients.

There were no reported events of major hypoglycemia in these five comparator-controlled 24-30 week trials. Major hypoglycemia was defined as loss of consciousness, seizure or coma (or other mental status change consistent with neuroglycopenia in the judgment of the investigator or physician) which resolved after administration of glucagon or glucose or required third party assistance to resolve because of severe impairment in consciousness or behavior. Patients were to have a concomitant glucose <54 mg/dL.

Abbreviations: N = The number of intent-to-treat patients.
†Patients in the sitagliptin, pioglitazone and metformin treatment groups received weekly placebo injections.
N/A = Not applicable.
Bydureon did not affect the absorption of orally administered acetaminophen. Nausea was the most common adverse reaction associated with initiation of treatment with BYDUREON, and usually decreased over time.

Injection Site Reactions

In the five comparator-controlled 24-30 week trials, injection site reactions were observed more frequently in patients treated with BYDUREON (17.1%) than in patients treated with BYETTA (12.4%), titrated insulin glargine (1.8%) or those patients who received placebo injections (statipiglizone (10.6%), peglotizzone (6.4%), and metformin (13.0%) treatment groups). These reactions for patients treated with BYDUREON were more commonly observed in antibody-positive patients (14.2%) compared with antibody-negative patients (3.1%), with a greater incidence in those with higher titer antibodies [see Warnings and Precautions (5.6)]. Incidence of injection site reactions for patients treated with BYETTA was similar for antibody positive patients (5.8%) and antibody negative patients (7.0%). One percent of patients treated with BYDUREON withdrew due to injection site adverse reactions [injection site mass, injection site nodule, injection site pruritus, and injection site reaction].

Skin and Subcutaneous Tissue Disorders

alopecia

The following additional adverse reactions have been reported during post-approval use of BYETTA. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Allergy/Hypersensitivity: injection site reactions, generalized pruritus and/or urticaria, maculopapular rash, angioedema; anaphylactic reaction [see Warnings and Precautions (5.5)].

Drug Interactions: increased international normalized ratio (INR), sometimes associated with bleeding, with concomitant warfarin use [see Drug Interactions (7.2)].

Gastrointestinal: nausea, vomiting, and/or diarrhea resulting in dehydration; abdominal distension, abdominal pain, eructation, constipation, flatulence, acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death [see Adverse Reactions (6.2) and Warnings and Precautions (5.2)].

Skin and Subcutaneous Tissue Disorders: alopecia

7 DRUG INTERACTIONS

7.1 Orally Administered Drugs

Exenatide slow-gastro emptying. Therefore, BYDUREON has the potential to reduce the rate of absorption of orally administered drugs. Use caution when administering oral medications with BYDUREON [see Clinical Pharmacology (12.2)]. In patients with type 2 diabetes, BYDUREON did not affect the absorption of orally administered aminoglutethimide to any clinically relevant degree.

7.2 Warfarin

BYDUREON has not been studied with warfarin. However, in a drug interaction study, BYETTA did not have a significant effect on INR [see Clinical Pharmacology (12.3)]. There have been postmarketing reports for BYETTA of increased INR with concomitant use of warfarin. INR was increased 3.6- to 5.3-times, respectively, in patients who received BYETTA in clinical trials with concomitant warfarin use compared with those who received BYETTA alone [see Drug Interactions (7.2)].

17-times, respectively, the human exposure resulting from the recommended dose of 2 mg/week, based on area under the concentration curve (AUC) [see Nonclinical Toxicology (13.3)].

There was no evidence of malformations. Doses of 0.3, 1, and 3 mg/kg correspond to systemic exposures of 3, 7 and 17-times, respectively, the human exposure resulting from the recommended dose of 2 mg/week, based on area under the concentration curve (AUC) [see Nonclinical Toxicology (13.3)].

In developmental toxicity studies, pregnant animals received exenatide, the active ingredient of BYDUREON, subcutaneously during organogenesis. Specifically, fetuses from pregnant rabbits given subcutaneous doses of exenatide at 0.2, 2, 22, 220 mg/kg/day from gestation day 6 through 18 experienced irregular skeletal ossifications from exposures 4 times the human exposure resulting from the recommended dose of 2 mg/week, based on AUC. Fetuses from pregnant mice given subcutaneous doses of exenatide at 6, 68, or 760 mg/kg/day from gestation day 6 through 15 demonstrated reduced fetal renal and neonatal growth, cleft palate and skeletal effects at systemic exposure that is equivalent to the human exposure resulting from the recommended dose of 2 mg/week, based on AUC [see Nonclinical Toxicology (13.3)].

Lactating mice given subcutaneous doses of exenatide, the active ingredient of BYDUREON, at 6, 68, or 760 mg/kg/day from gestation day 6 through lactation day 20 (weaning), experienced an increased number of neonatal deaths. Deaths were observed on postpartum days 2-4 in dams given 6 mg/kg/day, a systemic exposure that is equivalent to the human exposure resulting from the recomained dose of 2 mg/week, based on AUC [see Nonclinical Toxicology (13.3)].

8.3 Nursing Mothers

Exenatide is present in the milk of lactating mice at concentrations less than or equal to 2.5% of the concentration in maternal plasma following subcutaneous dosing. It is not known whether exenatide is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for exenatide extended-release in animal studies, a decision should be made whether to discontinue nursing or to discontinue BYDUREON, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness of BYDUREON have not been established in pediatric patients. BYDUREON is not recommended for use in pediatric patients.

8.5 Geriatric Use

In the five comparator-controlled 24-30 week trials, BYDUREON was studied in 132 patients (16.6%) who were at least 65 years old and 20 patients who were at least 75 years old. No differences in safety (N = 152) and efficacy (N = 52) were observed between these patients and younger patients, but the small sample size for patients ≥75 years old limits conclusions.

In separate trials, BYETTA was studied in 282 patients at least 65 years old and in 16 patients at least 75 years old. No differences in safety and efficacy were observed between these patients and younger patients, but the small sample size for patients ≥75 years old limits conclusions.

Because elderly patients are more likely to have decreased renal function, use caution when initiating BYDUREON in the elderly.

10 OVERDOSE

There were no reports of overdose in the five comparator-controlled 24-30 week trials of BYDUREON. Effects of overdoses with BYETTA in clinical studies included severe nausea, severe vomiting, and rapidly declining blood glucose concentrations, including severe hypoglycemia requiring parenteral glucose administration. In the event of overdose, supportive or specific treatment should be initiated according to the patient's clinical signs and symptoms.

11 DESCRIPTION

BYDUREON (exenatide extended-release for injectable suspension) is supplied as a sterile powder to be suspended in the diluent included in the single-dose tray and administered by subcutaneous injection. Exenatide is a 39-amino acid synthetic peptide amide with an empirical formula of C184H282N50O60S and a molecular weight of 4186.6 Daltons. The amino acid sequence for exenatide is shown below:

H-Nis-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Leu-Ser-Gln-Glu-Met-Glu-Glu-Glu-Ala-Val-Leu-Phe-Ile-Leu-Tyr-Lys-Ain-Gly-Pro-Ser-Glu-Ala-Pro-Pro-Ser-NH2

BYDUREON is a white to off-white powder that is available in a dosage strength of 2 mg exenatide per vial. Exenatide is incorporated in an aqueous dispersion of microsphere formulation containing the 50:50 poly(DL-lactide-co-glycolide) polymer (37.2 mg per vial) along with sucrose (0.8 mg per vial). The powder must be suspended in the diluent prior to injection. The diluent is provided in a prefilled syringe. Each prefilled syringe delivers 0.65 mL of the diluent as a clear, colorless to pale yellow solution composed of carboxymethylcellulose sodium (23 mg), polyorbate 20 (0.77 mg), sodium phosphate monoakash (2.7 mg), sodium phosphate dibasic heptahydrate (0.52 mg), sodium chloride (15.0 mg), and water for injection.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Incretins, such as glucagon-like-peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta cell, suppresses inappropriate elevated glucagon secretion, and slows gastric emptying.

The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide is a GLP-1 receptor antagonist that has been shown to bind and activate the human GLP-1 receptor in vitro. This leads to an increase in both glucose-dependent synthesis of insulin and an increase in insulin secretion from insulinomas, by mechanisms involving cyclic AMP and/or other intracellular signaling pathways. Exenatide promotes insulin release from pancreatic beta cells in the presence of elevated glucose concentrations.
The effect of exenatide at therapeutic (253 pg/mL) and supratherapeutic (627 pg/mL) concentrations, following treatment for 14 weeks, when steady-state concentrations had been achieved (approximately 280 levels were measured during a mixed meal tolerance test in a subset of patients with type 2 diabetes mellitus. In a 30-week controlled study of exenatide extended-release compared to BYETTA, postprandial glucose fasting and postprandial glucose food intake: Infusion of exenatide in eight healthy subjects resulted in a 19% decrease in caloric intake following gastric emptying: Exenatide slows gastric emptying, thereby reducing the rate at which postprandial glucose appears glucagon secretion: In patients with type 2 diabetes, exenatide moderates glucagon secretion and lowers serum gastric emptying increased by 30% when the OC was administered 30 minutes after BYETTA administration injection as compared to when the OC was given alone. Exenatide did not alter the mean trough concentrations of levonorgestrel after repeated daily dosing of the oral contraceptive for both regimens. However, the mean trough concentration of ethinyl estradiol was increased by 20% when the OC was administered 30 minutes after BYETTA administration injection as compared to when the OC was given alone. The effect of BYETTA on OC pharmacokinetics is confounded by the possible food effect on OC in this study (See Drug Interactions (7.7)). Warfarin: Administration of warfarin (25 mg) 35 minutes after repeated doses of BYETTA (10 mcg twice-daily) on days 1-2 and 10 mcg twice-daily on days 3-9 in healthy volunteers delayed warfarin T-max by approximately 2 hours. No clinically relevant effects on Cmax or AUC of warfarin were observed. BYETTA did not significantly alter the pharmacodynamic properties (e.g., international normalized ratio) of warfarin (see Drug Interactions (7.7)). Specific Populations Renal Impairment: BYDUREON has not been studied in patients with severe renal impairment (creatinine clearance < 10 ml/min) or end-stage renal disease receiving dialysis. Population pharmacokinetic analysis of renally impaired patients receiving 2 mg BYDUREON indicate that there is a 62% and 33% increase in exposure in moderate (N=10) and mild (N=56) renally-impaired patients, respectively as compared to patients with normal renal function (N=84). In a study of BYETTA in subjects with end-stage renal disease receiving dialysis, mean exenatide exposure increased by 3.4-fold compared to that of subjects with normal renal function (see Use in Specific Populations (8.6)). Hepatic Impairment: BYDUREON has not been studied in patients with acute or chronic hepatic impairment (see Use in Specific Populations (8.7)). Age: Population pharmacokinetic analysis of patients ranging from 22 to 73 years of age suggests that age does not influence the pharmacokinetic properties of exenatide (see Use in Specific Populations (8.5)). Gender: Population pharmacokinetic analysis suggests that gender does not influence the steady-state concentrations of exenatide following BYDUREON administration. Race: There were no apparent differences in steady-state concentrations of exenatide among Caucasian, Hispanic, and Black patients following BYDUREON administration. Body Mass Index: Population pharmacokinetic analysis of patients with body mass indices (BMI) >30 kg/m² and <30 kg/m² suggests that BMI has no significant effect on the pharmacokinetics of exenatide. Pediatric: BYDUREON has not been studied in pediatric patients (see Use in Specific Populations (8.4)). 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week carcinogenicity study was conducted with exenatide extended-release in male and female rats at doses of 1.0, 3.0 and 10.0 mg/kg, and 26 mg human systemic exposure based on AUC, respectively administered by subcutaneous injection every other week. A statistically significant increase in thyroid C-cell tumor incidence was observed in both male and females. The incidence of C-cell adenomas was statistically significantly increased at all doses (27% to 31%) in females and at 1.0 and 3.0 mg/kg (46% and 47%, respectively in males compared with the control group [11% for males and 7% for females]. A statistically significantly higher incidence of C-cell carcinomas occurred in the high dose group females (6%), while numerically higher incidences of 3%, 7%, and 4% (non-statistically significant versus controls) were noted in the low, mid, and high dose groups compared with the control group [0% for both males and females]. An increase in benign fibromas was seen in the skin subcutis at injection sites of males given 3 mg/kg. No treatment-related injection site fibromas were observed in females. The human systemic exposure based on AUC, respectively administered by once daily bolus subcutaneous injection. Benign thyroid C-cell adenomas were observed in female rats at all dosed mate doses. The incidence in females at all doses was 8% and 5% in the two control groups and 14%, 11%, and 23% in the low, medium, and high dose groups. In a 104-week carcinogenicity study with exenatide, the active ingredient in BYDUREON, in male and female rats at doses of 18, 70, or 250 mg/kg/day (3x, 21, and 72 times human systemic exposure based on AUC, respectively) administered by once daily bolus subcutaneous injection. Benign thyroid C-cell adenomas were observed in female rats at all dosed mate doses. The incidence at all rats for all dosed mate doses was 8% and 5% in the two control groups and 14%, 11%, and 23% in the low, medium, and high dose groups. In a 104-week carcinogenicity study with exenatide, the active ingredient in BYDUREON, in male and female mice at doses of 18, 70, or 250 mg/kg/day administered by once daily bolus subcutaneous injection, no evidence of tumors was observed at doses up to 250 mg/kg/day, a systemic exposure up to 16 times the human exposure
resulting from the recommended dose of 2 mg/week, based on AUC. The carcinogenicity of exenatide extended-release has not been evaluated in mice. BYDUREON and exenatide, the active ingredient in BYDUREON, were not mutagenic or clastogenic, with or without metabolic activation, in the Ames bacterial mutagenicity assay or chromosomal aberration assay in Chinese hamster ovary cells. Exenatide was negative in the in vivo mouse micronucleus assay. In mouse fertility studies with exenatide, the active ingredient in BYDUREON, beginning 2 weeks prior to and throughout mating until gestation day 7, there were no adverse fetal effects at doses up to 760 mcg/kg/day, systemic exposures up to 148 times the human exposure resulting from the maximum recommended dose of 2 mg/week, based on AUC. In pregnant mice given twice-daily subcutaneous doses of 6, 68, 460, or 760 mcg/kg/day exenatide, the active ingredient in BYDUREON, from gestation day 6 through 15 (organogenesis), irregular fetal skeletal ossifications were observed at 2 mcg/kg/day, a systemic exposure 4 times the human exposure resulting from the maximum recommended dose of 2 mg/kg/day, based on AUC. In pregnant rabbits given twice-daily subcutaneous doses of 0.2, 2, 22, 156, or 260 mcg/kg/day exenatide, the active ingredient in BYDUREON, from gestation day 6 through 18 (organogenesis), irregular fetal skeletal ossifications were observed at 2 mcg/kg/day, a systemic exposure 4 times the human exposure resulting from the maximum recommended dose of 2 mg/kg/day, based on AUC. In pregnant pigs given twice-daily subcutaneous doses of 6, 68, or 760 mcg/kg/day exenatide, the active ingredient in BYDUREON, from gestation day 6 through 15 (organogenesis), cleft palate (some with holes) and irregular fetal skeletal ossification of rib and skull bones were observed at 6 mcg/kg/day, a systemic exposure equal to the human exposure resulting from the maximum recommended dose of 2 mg/kg/day, based on AUC. In pregnant monkeys given twice-daily subcutaneous doses of 0.2, 0.65, 6.5, or 65 mcg/kg/day exenatide, the active ingredient in BYDUREON, from gestation day 6 through 15 (organogenesis), irregular fetal skeletal ossifications were observed at 0.65 mcg/kg/day, systemic exposure 14 times the human exposure resulting from the maximum recommended dose of 2 mg/kg/day, based on AUC. The carcinogenicity of exenatide extended-release in animals has not been evaluated. BYDUREON has been studied as monotherapy and in combination with metformin, a sulfonylurea, or a combination of metformin and a thiazolidinedione. BYDUREON has been studied as monotherapy and in combination with metformin, a sulfonylurea, a thiazolidinedione, or a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione. In a 24-week, randomized, open-label trial conducted to compare the safety and efficacy of BYETTA to BYETTA in patients with type 2 diabetes and inadequate glycemic control with diet and exercise alone or with oral antidiabetic therapy, including metformin, a sulfonylurea, a thiazolidinedione, or combination of two of these therapies. Twelve percent of 253 patients were studied: 149 (19%) were Caucasian, 78 (31%) Hispanic, 36 (14%) Black and 30 (12%) Asian. Seventy-five percent of patients were treated with diet and exercise alone (50%), a single oral antidiabetic agent (45%), or combination therapy of oral antidiabetic agents (5%). The mean baseline HbA1c was 8.4%. Patients were randomly assigned to receive BYDUREON 2 mg once every seven days (weekly) or BYETTA (10 mcg twice-daily), in addition to existing oral antidiabetic agents. Patients assigned to BYETTA initiated treatment with 5 mcg twice daily then increased the dose to 10 mcg twice-daily after 4 weeks. The endpoint was change in HbA1c from baseline to Week 24 (the last value at time of early discontinuation). Change in body weight was a secondary endpoint. Twenty-four week study results are summarized in Table 4. Each single-dose tray contains: • One vial containing 2 mg exenatide (as a white to off-white powder) • One prefilled syringe delivering 0.65 mL diluent • One vial connector • Two custom needles (23G, 5/16") specific to this delivery system (one is a spare needle) Do not substitute needles or any other components in the tray. 13.3 Reproductive and Developmental Toxicology A 13-week fetal developmental toxicity study was conducted with exenatide extended-release. A complete reproductive and developmental toxicity program was conducted with exenatide, the active ingredient in BYDUREON. Fetuses from pregnant rats given subcutaneous doses of exenatide extended-release at 0.3, 1 or 3 mg/kg on gestation days 6, 9, 12 and 15 demonstrated reduced fetal growth at all doses and produced skeletal ossification deficits at 1 and 3 mg/kg in association with maternal effects (decreased food intake and decreased body weight gain). There was no evidence of malformations. Doses of 0.3, 1 and 3 mg/kg correspond to systemic exposures of 3.7 and 17-times, respectively, the human exposure resulting from the recommended dose of 2 mg/kg/day, based on AUC. In female mice given twice-daily subcutaneous doses of 6, 68, or 760 mcg/kg/day exenatide, the active ingredient in BYDUREON, beginning 2 weeks prior to and throughout mating until gestation day 7, there were no adverse fetal effects at doses up to 760 mcg/kg/day, systemic exposures up to 148 times the human exposure resulting from the maximum recommended dose of 2 mg/kg/day, based on AUC. In pregnant mice given twice-daily subcutaneous doses of 6, 68, 460, or 760 mcg/kg/day exenatide, the active ingredient in BYDUREON, from gestation day 6 through 15 (organogenesis), cleft palate (some with holes) and irregular fetal skeletal ossification of rib and skull bones were observed at 6 mcg/kg/day, a systemic exposure equal to the human exposure resulting from the maximum recommended dose of 2 mg/kg/day, based on AUC. In pregnant rabbits given twice-daily subcutaneous doses of 0.2, 2, 22, 156, or 260 mcg/kg/day exenatide, the active ingredient in BYDUREON, from gestation day 6 through 18 (organogenesis), irregular fetal skeletal ossifications were observed at 2 mcg/kg/day, a systemic exposure 4 times the human exposure resulting from the maximum recommended dose of 2 mg/kg/day, based on AUC. In pregnant mice given twice-daily subcutaneous doses of 6, 68, or 760 mcg/kg/day exenatide, the active ingredient in BYDUREON, from gestation day 6 through 15 (organogenesis), cleft palate (some with holes) and irregular fetal skeletal ossification of rib and skull bones were observed at 6 mcg/kg/day, a systemic exposure equal to the human exposure resulting from the maximum recommended dose of 2 mg/kg/day, based on AUC. The carcinogenicity of exenatide extended-release in animals has not been evaluated. BYDUREON has been studied as monotherapy and in combination with metformin, a sulfonylurea, a thiazolidinedione, or a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione. In a 24-week, randomized, open-label trial conducted to compare the safety and efficacy of BYETTA to BYETTA in patients with type 2 diabetes and inadequate glycemic control with diet and exercise alone or with oral antidiabetic therapy, including metformin, a sulfonylurea, a thiazolidinedione, or combination of two of these therapies. Twelve percent of 253 patients were studied: 149 (19%) were Caucasian, 78 (31%) Hispanic, 36 (14%) Black and 30 (12%) Asian. Patients were treated with diet and exercise alone (50%), a single oral antidiabetic agent (47%), or combination therapy of oral antidiabetic agents (5%). The mean baseline HbA1c was 8.4%. Patients were randomly assigned to receive BYDUREON 2 mg once every seven days (weekly) or BYETTA (10 mcg twice-daily), in addition to existing oral antidiabetic agents. Patients assigned to BYETTA initiated treatment with 5 mcg twice daily then increased the dose to 10 mcg twice-daily after 4 weeks. The endpoint was change in HbA1c from baseline to Week 24 (the last value at time of early discontinuation). Change in body weight was a secondary endpoint. Twenty-four week study results are summarized in Table 4. Table 4: Results of 24-week Trial of BYDUREON

<table>
<thead>
<tr>
<th>BYDUREON</th>
<th>BYETTA</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mg</td>
<td>10 mcg</td>
</tr>
</tbody>
</table>

Intent-to-Treat Population (N) 129 123
HbA1c (%) Mean Baseline 8.5 8.4
Mean Change at Week 24 -1.6 -0.9
Difference from BYETTA (95% CI) -0.7 [-0.9, -0.4]*
Percentage Achieving HbA1c <7% at Week 24 58% 30%

Pacimal Plasma Glucose (mg/dL) Mean Baseline 168
Mean Change at Week 24 -25 -5
Difference from BYETTA (95% CI) -20 [-31, -10]*

N = The number of patients in each treatment group.
*BYETTA 5 mcg twice daily before the morning and evening meals for 4 weeks followed by 10 mcg twice daily for 20 weeks. Least squares means are adjusted for baseline HbA1c, stratum, background antihyperglycemic therapy, and baseline value of the dependent variable (if applicable). * p < 0.05, treatment vs. comparator.

Fasting mean baseline (97/44 mg/dL) was 79/44 mg/dL. Weight was slightly higher in both BYDUREON (-2.3 kg) and BYETTA (-1.4 kg) treatment groups. BYDUREON did not have adverse effects on blood pressure. An LS mean increase from baseline (74 beats per minute) in heart rate of 4 beats per minute was observed with BYDUREON treatment and 2 beats per minute with BYETTA treatment. The long-term effects of the increase in pulse rate have not been established (see Warnings and Precautions (5.8)).

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

BYDUREON (exenatide extended-release for injectable suspension) for once every seven days (weekly) subcutaneous administration is supplied in cartons of 4 single-dose trays for use (NDC 66780-219-04).

BYDUREON and exenatide, the active ingredient in BYDUREON, are red-brown to red-brown in color, and are supplied in a white plastic vial containing one vial of BYETTA, a prefilled syringe delivering 0.65 mL of diluent and a vial connector. The BYDUREON diluent is supplied in cartons of 4 single-dose trays for use (NDC 66780-219-04).
What is BYDUREON?

BYDUREON™ (by-DUR-ee-on)
(exenatide extended-release for injectable suspension)

Read this Medication Guide and Instructions for Use before you start using BYDUREON and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. If you have questions about BYDUREON after reading this information, ask your healthcare provider or pharmacist.

What is the most important information I should know about BYDUREON?

Serious side effects may happen in people who take BYDUREON, including:

1. Possible thyroid tumors, including cancer. During the drug testing process, the medicine in BYDUREON caused rats to develop tumors of the thyroid gland. Some of these tumors were cancers. It is not known if BYDUREON will cause thyroid tumors or a type of thyroid cancer called medullary thyroid cancer in people.
   - Before you start taking BYDUREON, tell your healthcare provider if you or any of your family members have had thyroid cancer, especially medullary thyroid cancer, or Multiple Endocrine Neoplasia syndrome type 2. Do not take BYDUREON if you or any of your family members have medullary thyroid cancer, or if you have Multiple Endocrine Neoplasia syndrome type 2. People with these conditions already have a higher chance of developing medullary thyroid cancer in general and should not take BYDUREON.
   - While taking BYDUREON, tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.

2. Inflammation of the pancreas (pancreatitis), which may be severe and lead to death.

Before taking BYDUREON, tell your healthcare provider if you have had:
- pancreatitis
- stones in your gallbladder (gallstones)
- a history of alcoholism
- high blood triglyceride levels

These medical conditions can make you more likely to get pancreatitis. It is not known if having these conditions will lead to a higher chance of getting pancreatitis while taking BYDUREON.

Stop taking BYDUREON and call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may happen with or without vomiting. The pain may be felt going from your abdomen through to your back. This type of pain may be a symptom of pancreatitis.

What is BYDUREON?

- BYDUREON is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes mellitus, and should be used along with diet and exercise.
- BYDUREON is a long-acting form of the medication contained in BYETTA. Do not use BYDUREON and BYETTA together.
- BYDUREON is not recommended as the first choice of medication for treating diabetes.
- BYDUREON is not insulin.
- It is not known if BYDUREON is safe and effective when used with insulin.
- BYDUREON is not for use in people with type 1 diabetes or people with a condition caused by very high blood sugar (diabetic ketoacidosis).
- It is not known if BYDUREON is safe and effective in children. BYDUREON is not recommended for use in children.
- It is not known if BYDUREON is safe and effective in people who have a history of pancreatitis.
- BYDUREON has not been studied in people who have severe kidney problems.

Who should not use BYDUREON?

Do not use BYDUREON if:
- you or any of your family members have a history of medullary thyroid cancer.
- you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a disease where people have tumors in more than one gland in their body.
- you are allergic to exenatide or any of the ingredients in BYDUREON. See the end of this Medication Guide for a complete list of ingredients in BYDUREON. Symptoms of a severe allergic reaction may include:
  - swelling of your face, lips, tongue, or throat
  - problems breathing or swallowing
  - severe rash or itching

Talk to your healthcare provider before taking this medicine if you have any of these conditions.

What should I tell my healthcare provider before using BYDUREON?

Before using BYDUREON, tell your healthcare provider if you:
- have any of the conditions listed in the section “What is the most important information I should know about BYDUREON?”
- have severe problems with your stomach such as slow emptying of your stomach (gastroparesis) or problems digesting food.
- have or have had kidney problems, or have had a kidney transplant.
- have any other medical conditions.
- are pregnant or are planning to become pregnant. It is not known if BYDUREON may harm your unborn baby. Tell your healthcare provider if you become pregnant while taking BYDUREON.
- Pregnancy Registry: Amylin Pharmaceuticals, Inc. has a registry for women who take BYDUREON during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you take BYDUREON at any time during pregnancy, you may enroll in this registry by calling 1-800-633-9081.
- are breastfeeding or plan to breastfeed. It is not known if BYDUREON passes into your breast milk. You and your healthcare provider should decide if you will take BYDUREON or breastfeed. You should not do both without talking with your healthcare provider first.

Tell your healthcare provider about all of the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. BYDUREON may affect the way some medicines work and some other medicines may affect the way BYDUREON works.

Especially tell your healthcare provider if you take:
- other diabetes medicines, especially insulin or a sulfonylurea
- any medicine taken by mouth
- warfarin sodium (Coumadin®, Jantoven®)

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine.

How should I use BYDUREON?

For detailed instructions, see the Instructions for Use that comes with your BYDUREON.

- Use BYDUREON exactly as your healthcare provider tells you to.
- Use BYDUREON exactly as your healthcare provider tells you to.
- Use BYDUREON exactly as your healthcare provider tells you to.
- Use BYDUREON exactly as your healthcare provider tells you to.
- Use BYDUREON exactly as your healthcare provider tells you to.
Follow your healthcare provider's instructions for diet, exercise, how often to test your blood sugar, and when to get your HbA1c checked. If you see your blood sugar increasing during treatment with BYDUREON, talk to your healthcare provider because you may need to adjust your current treatment plan for your diabetes.

Talk to your healthcare provider about how to manage high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia), and how to recognize problems that can happen with your diabetes.

What are the possible side effects of BYDUREON?
BYDUREON can cause serious side effects, including:

- See “What is the most important information I should know about BYDUREON?”
- Low blood sugar (hypoglycemia). Your risk for getting low blood sugar is higher if you take BYDUREON with another medicine that can cause low blood sugar, such as a sulfonylurea. The dose of your sulfonylurea medicine may need to be lowered while you use BYDUREON. Signs and symptoms of low blood sugar may include:
  - shakiness
  - sweating
  - headache
  - drowsiness
  - weakness
  - dizziness

Talk with your healthcare provider about how to recognize and treat low blood sugar. Make sure that your family and other people around you a lot know how to recognize and treat low blood sugar.

- Kidney problems (kidney failure). BYDUREON may cause nausea, vomiting or diarrhea leading to loss of fluids (dehydration). Dehydration may cause kidney failure, which can lead to the need for dialysis. This can happen in people who have never had kidney problems before. Drinking plenty of fluids may reduce your chance of dehydration. Call your healthcare provider right away if you have nausea, vomiting, or diarrhea that will not go away, or if you cannot drink liquids by mouth.

- Severe allergic reactions. Severe allergic reactions can happen with BYDUREON. Stop taking BYDUREON, and get medical help right away if you have any symptom of a severe allergic reaction. See “Who should not take BYDUREON?”

The most common side effects of BYDUREON include:
- nausea
- diarrhea
- headache
- vomiting
- constipation
- indigestion

Nausea is most common when you first start using BYDUREON, but decreases over time in most people as their body gets used to the medicine. Talk to your healthcare provider about any side effect that bothers you or does not go away. These are not all the side effects of BYDUREON. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store BYDUREON?
- Store BYDUREON in the refrigerator at 36°F to 46°F (2°C to 8°C).
- Do not use BYDUREON past the expiration date. The expiration date is labeled EXP and can be found on the paper cover of the single-dose tray.
- Do not freeze BYDUREON trays. Do not use BYDUREON if it has been frozen.
- Protect BYDUREON from light until you are ready to prepare and use your dose.
- If needed, you can keep your BYDUREON tray out of the refrigerator at 68°F to 77°F (20°C to 25°C) for up to 4 weeks.
- See the Instructions for Use for information about how to throw away your used BYDUREON parts.

Keep BYDUREON, and all medicines, out of the reach of children.

General information about safe and effective use of BYDUREON
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BYDUREON for a condition for which it was not prescribed. Do not give your BYDUREON to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about BYDUREON. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about BYDUREON that is written for healthcare professionals.

For more information about BYDUREON, go to www.BYDUREON.com or call 1-877-700-7365.

What are the ingredients in BYDUREON?
Contents of vial:
- Active ingredient: exenatide
- Inactive ingredients: polylactide-co-glycolide and sucrose.

Contents of liquid (diluent) in syringe:
- Inactive ingredients: carbomethylcellulose sodium, polysorbate 20, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, sodium chloride, water for injection.

This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: January 2012
Manufactured by Amylin Pharmaceuticals, Inc., San Diego, CA 92121.
BYDUREON is a trademark and BYETTA is a registered trademark of Amylin Pharmaceuticals, Inc. All other marks are the marks of their respective owners.
© 2012 Amylin Pharmaceuticals, Inc. All rights reserved.
833001-FF
08-11-12815-A
Please see Important Safety Information on pages 6 and 7, and the accompanying Prescribing Information and Medication Guide.
Please see Important Safety Information on pages 6 and 7, and the accompanying Prescribing Information and Medication Guide.